JPWO2020082950A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020082950A5
JPWO2020082950A5 JP2021523243A JP2021523243A JPWO2020082950A5 JP WO2020082950 A5 JPWO2020082950 A5 JP WO2020082950A5 JP 2021523243 A JP2021523243 A JP 2021523243A JP 2021523243 A JP2021523243 A JP 2021523243A JP WO2020082950 A5 JPWO2020082950 A5 JP WO2020082950A5
Authority
JP
Japan
Prior art keywords
sphingosine kinase
drug
present
protein
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021523243A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512843A (ja
JP2022512843A5 (https=
Publication date
Priority claimed from CN201811225720.2A external-priority patent/CN109355269B/zh
Application filed filed Critical
Publication of JP2022512843A publication Critical patent/JP2022512843A/ja
Publication of JP2022512843A5 publication Critical patent/JP2022512843A5/ja
Publication of JPWO2020082950A5 publication Critical patent/JPWO2020082950A5/ja
Pending legal-status Critical Current

Links

JP2021523243A 2018-10-21 2019-09-20 スフィンゴシンキナーゼ１とその融合タンパク質およびその使用 Pending JP2022512843A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811225720.2A CN109355269B (zh) 2018-10-21 2018-10-21 鞘氨醇激酶1及其融合蛋白及其用途
CN201811225720.2 2018-10-21
PCT/CN2019/107091 WO2020082950A1 (zh) 2018-10-21 2019-09-20 鞘氨醇激酶1及其融合蛋白及其用途

Publications (3)

Publication Number Publication Date
JP2022512843A JP2022512843A (ja) 2022-02-07
JP2022512843A5 JP2022512843A5 (https=) 2023-04-05
JPWO2020082950A5 true JPWO2020082950A5 (https=) 2023-04-05

Family

ID=65345959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523243A Pending JP2022512843A (ja) 2018-10-21 2019-09-20 スフィンゴシンキナーゼ１とその融合タンパク質およびその使用

Country Status (4)

Country Link
US (1) US20210388326A1 (https=)
JP (1) JP2022512843A (https=)
CN (1) CN109355269B (https=)
WO (1) WO2020082950A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109355269B (zh) * 2018-10-21 2020-03-24 北京双因生物科技有限公司 鞘氨醇激酶1及其融合蛋白及其用途
CN111303298B (zh) * 2020-02-19 2023-03-21 李瑛� 含有磷酸酶的融合蛋白及其产品和应用
CN112143705B (zh) * 2020-09-23 2022-09-06 北京华奥玄德生物医药科技有限公司 一种双基因修饰的干细胞及其用途
CN114762724A (zh) * 2020-12-31 2022-07-19 吴伯骥 HrpWEch蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用
CN114762723A (zh) * 2020-12-31 2022-07-19 吴伯骥 HrpZpst蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用
CN112675293A (zh) * 2020-12-31 2021-04-20 吴伯骥 HrpNEcb蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512072A (ja) * 1999-10-28 2003-04-02 ワーナー−ランバート・カンパニー ヒトスフィンゴシンキナーゼ遺伝子
US6610534B2 (en) * 2000-10-05 2003-08-26 Novartis Ag Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases
WO2004061107A1 (ja) * 2002-12-27 2004-07-22 The New Industry Research Organization スフィンゴシンキナーゼ２を利用した細胞増殖抑制剤、その核移行シグナルを持つ融合タンパク質の作製方法、及び薬剤候補物質のスクリーニング方法、並びにスクリーニングキット
WO2014135984A2 (en) * 2013-03-07 2014-09-12 Recopharma Ab Glycosylated mucin-immunoglobulin fusion protein coated device
JP6324137B2 (ja) * 2014-03-24 2018-05-16 ジヤトコ株式会社 シール機構付き車両用無段変速機
CN106279430B (zh) * 2015-06-30 2017-11-28 安源医药科技（上海）有限公司 Exendin‑4类似物融合蛋白及其制备方法和用途
CN106432511A (zh) * 2016-09-29 2017-02-22 上海凯茂生物医药有限公司 GLP‑1类似物‑Fc融合蛋白及其制备方法和用途
CN107875398B (zh) * 2017-09-27 2021-03-23 浙江大学 一种抗体偶联药物的制备方法、抗体偶联药物及应用
CN109355269B (zh) * 2018-10-21 2020-03-24 北京双因生物科技有限公司 鞘氨醇激酶1及其融合蛋白及其用途

Similar Documents

Publication Publication Date Title
Pieber et al. Comparison of three multiple injection regimens for type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin
TW201100093A (en) Preparation comprising insulin, nicotinamide and an amino acid
CN105142661B (zh) 通过长效胰岛素制剂治疗糖尿病
CN102380091A (zh) 白介素-22在治疗病毒性肝炎中的应用
CN101361968A (zh) 白介素-22在治疗脂肪肝中的应用
Lepore et al. Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily...
JP2025163025A (ja) 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法
CN105944103B (zh) 一种口服复方天然降糖药物
JPWO2020082950A5 (https=)
CN103536904A (zh) Metrnl蛋白在制备降血糖药物方面的应用
CN111265523A (zh) 小檗碱、人参皂苷组合物在制备预防和/或治疗糖尿病伴发抑郁症的药物中的应用
US10342852B2 (en) Methods of reducing blood glucose or triglyceride levels by administration of METRNL protein
CN110038114B (zh) 一种多肽在制备预防或治疗代谢综合征药物中的用途
WO2020103889A1 (zh) 抑郁症治疗方法和药物
WO2022061962A1 (zh) 一种l型氨基酸转运蛋白抑制剂或拮抗剂有效干预糖尿病的方法
CN106943408B (zh) 四甲基尿酸预防和治疗糖尿病的应用
Tian et al. Spleen-kidney supplementing formula alleviates insulin resistance via regulating AKT/glycogen synthase kinase 3β pathway in rats with type 2 diabetic induced by high-fat diet
Cypryk et al. New faster-acting insulin Fiasp®—do we need a new meal-time insulin?
CN101219208B (zh) 白介素-22的医药用途
CN108478583A (zh) 二氟尼柳在制备预防和治疗糖尿病药物中的应用
CN112010971A (zh) 抗vegf抗体在制备预防和/或治疗脂肪肝的药物中的应用
CN112972658B (zh) 一种生长激素或其类似物的口服药物组合物
GB2476789A (en) Use of thymosin for treatment of type 2 diabetes
Wang A Comparative Analysis of Insulin Glargine and New Insulin Analog LY IGlar in Diabetes Treatment
CN107823338A (zh) 一种金花茶提取物在治疗糖尿病药物中的应用